Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.

@article{Schlueter2016ComparativeEO,
  title={Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.},
  author={Max Schlueter and N{\'u}ria Gonz{\'a}lez-Rojas and Michael K. Baldwin and Lars Groenke and Florian Vo\ss and Tim Reason},
  journal={Therapeutic advances in respiratory disease},
  year={2016},
  volume={10 2},
  pages={89-104}
}
BACKGROUND A number of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) fixed-dose combinations (FDCs) for treatment of moderate-to-very severe chronic obstructive pulmonary disease (COPD) have recently become available, but none have been directly compared in head-to-head randomized controlled trials (RCTs). The purpose of this study was to assess the relative clinical benefit of all currently available LAMA/LABA FDCs using a Bayesian network meta-analysis (NMA… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS